#neverforget – Photobiomodulation Against Alzheimer’s Disease: A Systematic Review

This systematic review evaluates photobiomodulation (PBM) as a potential therapeutic approach for Alzheimer’s disease (AD). The paper explores how red and near-infrared light may improve brain mitochondrial function, reduce neuronal damage, and support neuroprotection. It reviews experimental, animal, and early human evidence, highlighting PBM as a promising non-invasive strategy for slowing neurodegeneration and improving cognitive outcomes, though larger clinical trials are still needed.

Key points:

• Mitochondrial support – PBM may improve mitochondrial activity and ATP production, helping maintain neuronal energy metabolism.
• Neuroprotection – It may reduce oxidative stress, inflammation, and neuronal apoptosis (cell death), which are major contributors to Alzheimer’s progression.
• Potential cognitive benefits – Early findings suggest PBM may support memory, cognition, and brain function.
• Preclinical evidence – In vitro and animal studies showed encouraging results for reducing amyloid-related damage and improving neurological outcomes.
• Human evidence is limited – Early case studies and preliminary clinical findings were promising, but large-scale human trials were lacking.
• Non-invasive therapy – PBM is highlighted as a relatively safe and low-risk treatment option for neurological disease research.
• Future direction – The review recommends stronger clinical trials and optimized protocols to move PBM from experimental use to broader clinical practice.

Simple takeaway:
Photobiomodulation shows potential as a non-invasive supportive therapy for Alzheimer’s disease by improving brain energy metabolism, reducing oxidative stress, and protecting neurons, but stronger human clinical evidence is needed before widespread clinical adoption.